Sugamori K S, Scheideler M A, Vernier P, Niznik H B
Department of Pharmacology, University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada.
J Neurochem. 1998 Dec;71(6):2593-9. doi: 10.1046/j.1471-4159.1998.71062593.x.
NNC 01-0012, a second-generation benzazepine compound, pharmacologically differentiates multiple vertebrate D1 receptor subtypes (D1A, D1B, D1C, and D1D) and displays high selectivity and affinity for dopamine D1C receptors. Functionally, whereas NNC 01-0012 acts as a full or poor antagonist at D1C and D1A receptor-mediated cyclic AMP production, respectively, it exhibits partial agonist activity at the D1B receptor. To define some of the structural motifs that regulate the pharmacological and functional differentiation of vertebrate dopamine D1 receptors by NNC 01-0012, a series of receptor chimeras were constructed in which the divergent carboxyl-terminal (CT) receptor tails were replaced with the corresponding sequences of D1A, D1B, or D1C receptors. Substitution of the vertebrate D1B carboxyl-terminal-tail at position Tyr345 with carboxyl-terminal-tail sequences of the D1A receptor abolished the partial agonist activity of NNC 01-0012 without affecting dopamine-stimulated cyclic AMP accumulation. At vertebrate D1B/D1CcT-tail receptor mutants, however, the intrinsic activity of the partial agonist NNC 01-0012 (10 microM) was markedly enhanced (approximately 60% relative to 10 microM dopamine) with no concomitant alteration in the molecule's ligand binding affinity or constitutive activity of the chimeric receptor. Similar results were obtained with other benzazepines such as SKF-38393 and SCH-23390, which act as partial agonists at vertebrate D1B receptors. Substitution of D1A and D1C receptor carboxyl-terminal tails with sequences encoded by the D1B receptor carboxyl-terminal tail did not, however, produce receptors with functional characteristics significantly different from wild type. Taken together, these data clearly suggest that in addition to well-characterized domains and amino acid residues in the third cytoplasmic loop, partial agonist activity at the D1B receptor is modulated by sequence-specific motifs within the carboxyl-terminal tail, a region that may underlie the possible structural basis for functionally divergent roles of multiple dopamine D1-like receptors.
NNC 01 - 0012是一种第二代苯并氮杂卓化合物,在药理学上可区分多种脊椎动物D1受体亚型(D1A、D1B、D1C和D1D),并对多巴胺D1C受体表现出高选择性和亲和力。在功能上,NNC 01 - 0012分别作为D1C和D1A受体介导的环磷酸腺苷(cAMP)产生的完全拮抗剂或低效拮抗剂,但在D1B受体上表现出部分激动剂活性。为了确定一些通过NNC 01 - 0012调节脊椎动物多巴胺D1受体药理学和功能差异的结构基序,构建了一系列受体嵌合体,其中不同的羧基末端(CT)受体尾巴被D1A、D1B或D1C受体的相应序列取代。将脊椎动物D1B受体第345位酪氨酸处的羧基末端尾巴替换为D1A受体的羧基末端尾巴序列,消除了NNC 01 - 0012的部分激动剂活性,而不影响多巴胺刺激的cAMP积累。然而,在脊椎动物D1B/D1CcT - 尾巴受体突变体中,部分激动剂NNC 01 - 0012(10μM)的内在活性显著增强(相对于10μM多巴胺约为60%),而分子的配体结合亲和力或嵌合受体的组成活性没有相应改变。用其他苯并氮杂卓如SKF - 38393和SCH - 23390也得到了类似结果,它们在脊椎动物D1B受体上作为部分激动剂起作用。然而,用D1B受体羧基末端尾巴编码的序列替换D1A和D1C受体的羧基末端尾巴,并没有产生功能特性与野生型显著不同的受体。综上所述,这些数据清楚地表明,除了第三细胞质环中已明确的结构域和氨基酸残基外,D1B受体上的部分激动剂活性还受到羧基末端尾巴内序列特异性基序的调节,该区域可能是多种多巴胺D1样受体功能不同作用的可能结构基础。